Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 5, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3917

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 697–708 of 3,917 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Starting the Conversation (STC), Time and Attention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions: Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 63
States / cities: Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more

Conditions: Prostate Cancer, Oligoprogressive, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions: Ablative local therapy; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Saruparib (AZD5305), Darolutamide, No Treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan • Providence, Rhode Island

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years to 79 Years · Male only
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Fasting, Ketone Supplementation; Behavioral · Dietary Supplement
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT); Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer, Cancer of Prostate
Interventions: Dapagliflozin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions: Cryosurgery, High-Intensity Focused Ultrasound Ablation, Survey Administration; Procedure · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Fluciclovine PET/CT; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: XL092; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

About this Prostate Cancer clinical trials directory page